Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:e407414ebcb2b4ac1a2175d8544e98d9]
To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]
Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:e407414ebcb2b4ac1a2175d8544e98d9]
To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
Bio2RDF identifier
e407414ebcb2b4ac1a2175d8544e98d9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e407414ebcb2b4ac1a2175d8544e98d9
measure [clinicaltrials_vocabulary:measure]
Number of participants with serious and non-serious adverse events
time frame [clinicaltrials_vocabulary:time-frame]
description
To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
identifier
clinicaltrials_resource:e407414ebcb2b4ac1a2175d8544e98d9
title
Number of participants with serious and non-serious adverse events 30 days
@en
type
label
Number of participants with se ...... 7414ebcb2b4ac1a2175d8544e98d9]
@en